You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

This page is for Healthcare Professionals only.  If you are not a Healthcare Professional, please visit SHINGRIX.ca.

SHINGRIX: New from GSK | Coming in January 2018

Click to learn more

SHINGRIX Herpes Zoster vaccine (non-live recombinant, AS01B adjuvanted) is indicated for:

  • Prevention of herpes zoster (HZ, or shingles) in adults 50 years of age or older.1

 

Indications and clinical use:

  • Indicated for prevention of herpes zoster (HZ, or shingles) in adults 50 years of age or older

Most serious warnings and precautions:

  • Administration: Do not administer the vaccine intravascularly, intradermally or subcutaneously.

Other relevant warnings and precautions:

  • A protective immune response may not be elicited in all vaccines
  • Not for prevention of primary varicella infection or treatment of HZ or postherpetic neuralgia
  • Postpone in those with acute severe febrile illness
  • Use with caution in those with thrombocytopenia or any coagulation disorder
  • Syncope may occur following or before any vaccination as a psychogenic response
  • Use in special populations such as pregnant or nursing women or pediatrics (<18 years of age) has not been established
  • Limited data in immunocompromised adults 50 years of age or older

Adverse events:

  • Solicited local and general adverse reactions that occurred in clinical trials within 7 days of vaccination in subjects aged 50–69 and ≥70 years respectively were: pain (85%, 69.2%), redness (38.5%, 37.7%), swelling at the injection site (28.5%, 23.0%), myalgia (53.0%, 35.1%), fatigue (51.3%, 36.6%), headache (45.2%, 29.0%), shivering (33.1%, 19.5%), fever (25.9%, 14.3%), gastrointestinal symptoms (20.5%, 13.5%)
  • Unsolicited adverse reactions that occurred in clinical trials within 30 days of vaccination in ≥1% of subjects and ≥2-fold higher than placebo recipients included chills (3.5%), injection site pruritus (2.2%), and malaise (1.7%)

For more information

Please consult the product monograph at gsk.ca/SHINGRIX/PM for important information relating to dosing and administration, adverse reactions, contraindications and drug interactions which have not been discussed in this piece. To request a product monograph, or to report an adverse event please call 1-800-387-7374.

Reference:

SHINGRIX Product Monograph. GlaxoSmithKline Inc., October 13, 2017.